Cancer Genetics is Pleased to Announce the Appointment of Dr. Paul Rothman, Dean of the Medical Faculty and CEO of Johns Hopkins Medicine, to Its Board of Directors

RUTHERFORD, N.J., Feb. 18, 2014 (GLOBE NEWSWIRE) -- Cancer Genetics (Nasdaq:CGIX), an emerging leader in DNA-based diagnostics, announced today the addition of Paul Rothman, MD, Dean of the Medical Faculty and CEO of Johns Hopkins Medicine, to the Company's Board of Directors.

As Dean and CEO, Dr. Rothman oversees both the Johns Hopkins Health System and the School of Medicine. He joined Johns Hopkins in July 2012, after having served as the Dean of the Carver College of Medicine at the University of Iowa and the leader of its clinical practice plan since 2008.  Previously, he served as head of internal medicine at the University of Iowa, and prior to that, was vice chairman for research and founding director of the Division of Pulmonary, Allergy and Critical Care Medicine at Columbia University College of Physicians and Surgeons, where he joined the faculty in 1986.  He is a Phi Beta Kappa graduate of the Massachusetts Institute of Technology and earned his medical degree from Yale University.  He trained at Columbia-Presbyterian Medical Center and accepted a postdoctoral fellowship at Columbia University prior to joining its school faculty.  

"We are very pleased to have Dr. Rothman join our board of directors," said Panna Sharma, President and Chief Executive Officer of Cancer Genetics.  "Dr. Rothman's vast experience, including his ability to lead innovative research in oncology and his broad knowledge of the US healthcare system will be highly valuable to our organization. As we strive to develop products that transform cancer patient management, improve treatment outcomes, and reduce healthcare costs, his guidance can help provide us valuable strategic insights." 

Dr. Rothman's research has focused on the role cytokines play in the normal development of blood cells, as well as the abnormal development of these blood cells as a cause of hematological cancers, including leukemias. He also studied the role of cytokines in immune system responses to asthma and allergies. His work has been consistently funded by the National Institutes of Health.

Dr. Rothman's honors include a James S. McDonnell Foundation Career Development Award, a Pfizer Scholars Award, a Pew Scholar Award, a Leukemia Society of America Scholar Award and the Pharmacia Allergy Research Foundation International Award in 1997. Dr. Rothman is a member of the American Society for Clinical Investigation and is a Fellow of the American College of Physicians. He was elected to the Council of Association of American Physicians, as a Fellow of the American Association for the Advancement of Sciences, and as a member of the American Clinical and Climatological Association.

Cancer Genetics also announced the resignation of Andrew Pecora from its Board of Directors.  "We would like to thank Andrew for his many years of leadership at Cancer Genetics and his crucial role in the development of our Company.  We wish him well in his endeavors," said Panna Sharma.

About Cancer Genetics:

Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics, servicing some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals, as well as biopharma and biotech companies. Our state-of-the-art reference lab is focused entirely on maintaining clinical excellence and is both CLIA certified and CAP accredited and has licensure from several states including New York State. We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute. For further information, please see

Forward Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Company's Form 10-Q for the quarter ended September 30, 2013 and other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.


Contact Data